Haplo Pharmaceuticals-B (02142.HK) and Bristol-Myers Squibb entered into a global strategic partnership and licensing agreement.

Tencent Finance News, Haoboyi Medicine-B (02142.HK) announced on December 17, 2025 that the company has signed a long-term global strategic cooperation and licensing agreement with Bristol-Myers Squibb to discover and develop a new generation of multi-specific antibodies.